KLOW blend
GHK-Cu + BPC-157 + TB-500 + KPV
KLOW is a compounded four-peptide mixture — GHK-Cu, KPV, BPC-157 and TB-500 — sold for skin, joint and tissue-repair support. It has never been studied as a combination.
Regulatory status: Not an FDA-approved drug. It is a compounded or research-chemical mixture, and no regulator has reviewed the blend. BPC-157 specifically was reviewed by the FDA's Pharmacy Compounding Advisory Committee, which found insufficient safety and effectiveness data.
Default vial
80 mg
Default mix
3 mL
Reported range
300–600 mcg of blend
Draw (U-100)
1.9 u
Gut- and tissue-repair blend, typically GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg in one vial. Blend ratios vary by supplier — confirm the mg of each component on your COA before dosing.
What it is
- Four peptides with different proposed mechanisms combined in one vial.
- Component ratios and concentrations vary by supplier; only a Certificate of Analysis can confirm the actual contents.
- None of the four components is an FDA-approved drug.
- Sold through peptide vendors and compounding pharmacies rather than standard prescription channels.
How it is described to act
- 1
Injected subcutaneously in practice, though no dosing regimen for the combination has been studied.
- 2
Each component distributes according to its own properties; no combined pharmacokinetic data exist.
- 3
GHK-Cu is proposed to support collagen remodelling, KPV to reduce inflammation via melanocortin-related signalling, BPC-157 to support tissue repair in rodents, and TB-500 to aid cell migration in preclinical models.
- 4
No study has evaluated the four peptides together, so any 'synergy' claim is an extrapolation from separate animal and cell work.
What the research has looked at
What exists is component-level only
- GHK-Cu has been reviewed for skin-regeneration and cell-signalling effects (BioMed Res Int, 2015; Aging Pathobiol Ther, 2020).
- BPC-157 has been reviewed for gastroprotective and organoprotective effects in rodent models (Gut and Liver, 2020; Curr Pharm Des, 2020).
- KPV has been studied for anti-inflammatory keratinocyte signalling in vitro (J Invest Dermatol, 2004).
What does not exist
- PubMed and ClinicalTrials.gov searches returned no study of the four-peptide combination, and no FDA or FTC document addresses 'KLOW' by name.
Strength of evidence: Preclinical evidence only
There is no evidence for the blend itself. The component evidence is preclinical, and combining four unstudied compounds does not inherit the evidence of any of them.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- Combining four unapproved compounds multiplies unknown interaction risks.
- There are no combined pharmacokinetic or toxicity data for any of these blends, so interaction risk is unquantified.
- The FDA's 2026 compounding-committee briefing on BPC-157 documented adverse-event reports and gaps in impurity characterisation for that single peptide.
- Sterility, identity and concentration of multi-peptide compounded vials vary by supplier; only a current third-party Certificate of Analysis can confirm what a vial actually contains.
References
- 1.FDA PCAC briefing document: BPC-157-related bulk drug substances (2026)
- 2.Sikiric et al. Stable gastric pentadecapeptide BPC 157, Gut and Liver (2020)
- 3.Pickart et al. GHK peptide as a natural modulator of skin regeneration, BioMed Res Int (2015)
- 4.alpha-MSH, MSH 11-13 KPV and ACTH signalling in human keratinocytes, J Invest Dermatol (2004)
Handling this vial
- Blends complicate reconstitution maths: the label total is split across four peptides, so a single 'mg' figure does not tell you how much of each component a draw contains.
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
KLOW blend questions people ask
How do you reconstitute KLOW blend?
A common starting point for a 80 mg vial of KLOW blend is 3 mL of bacteriostatic water, which gives 26.67 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of KLOW blend is one dose?
At 26.67 mg per mL, that works out to about 1.9 units on a U-100 insulin syringe for a 500 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for KLOW blend?
Published and community sources describe 300–600 mcg of blend, subcutaneous, every day, typically run 6 weeks on and 2 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should KLOW blend be stored?
Lyophilized KLOW blend vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.